111 related articles for article (PubMed ID: 1984676)
1. Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Lindqvist U; Engström Laurent A
Am J Hematol; 1991 Jan; 36(1):1-8. PubMed ID: 1984676
[TBL] [Abstract][Full Text] [Related]
2. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy.
Hasselbalch H; Junker P; Hørslev-Petersen K; Lisse I; Bentsen KD
Am J Hematol; 1990 Jan; 33(1):18-26. PubMed ID: 2293759
[TBL] [Abstract][Full Text] [Related]
3. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
4. Serum procollagen III peptide in chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD
Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
[TBL] [Abstract][Full Text] [Related]
5. Serum laminin P1 in idiopathic myelofibrosis and related diseases.
Hasselbalch H; Junker P
Leuk Res; 1994 Aug; 18(8):623-8. PubMed ID: 8065164
[TBL] [Abstract][Full Text] [Related]
6. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD; Risteli L; Risteli J
Am J Hematol; 1986 Oct; 23(2):101-11. PubMed ID: 3752065
[TBL] [Abstract][Full Text] [Related]
7. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.
Jensen MK; Riisbro R; Holten-Andersen MN; Brown Pde N; Junker P; Brünner N; Hasselbalch HC
Eur J Haematol; 2003 Oct; 71(4):276-82. PubMed ID: 12950237
[TBL] [Abstract][Full Text] [Related]
8. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis.
Remmel T; Remmel H; Salupere V
J Gastroenterol Hepatol; 1996 Nov; 11(11):1016-20. PubMed ID: 8985819
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).
Taube T; Franssila K; Risteli L; Risteli J; Elomaa I
Br J Haematol; 1992 Sep; 82(1):32-7. PubMed ID: 1419800
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
Scheja A; Akesson A; Hørslev-Petersen K
Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489
[TBL] [Abstract][Full Text] [Related]
11. Different effects of thyroid disease on serum levels of procollagen III N-peptide and hyaluronic acid.
Faber J; Hørslev-Petersen K; Perrild H; Lorenzen I
J Clin Endocrinol Metab; 1990 Oct; 71(4):1016-21. PubMed ID: 2401705
[TBL] [Abstract][Full Text] [Related]
12. Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders.
Sréter L; Kárteszi M; Fehér J; Lutz D
Acta Med Hung; 1988; 45(3-4):323-8. PubMed ID: 3249659
[TBL] [Abstract][Full Text] [Related]
13. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
[TBL] [Abstract][Full Text] [Related]
14. Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome.
Nyberg A; Lindqvist U; Engström-Laurent A
J Intern Med; 1992 May; 231(5):485-91. PubMed ID: 1602286
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum.
Abildgaard N; Bendix-Hansen K; Kristensen JE; Vejlgaard T; Risteli L; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Dec; 99(3):641-8. PubMed ID: 9401078
[TBL] [Abstract][Full Text] [Related]
16. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
Arrago JP; Poirier O; Najean Y
Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
18. Hepatic and renal extraction of circulating type III procollagen amino-terminal propeptide and hyaluronan in pig.
Bentsen KD; Henriksen JH; Boesby S; Hørslev-Petersen K; Lorenzen I
J Hepatol; 1989 Sep; 9(2):177-83. PubMed ID: 2809157
[TBL] [Abstract][Full Text] [Related]
19. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
[TBL] [Abstract][Full Text] [Related]
20. Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease.
Sharif M; George E; Dieppe PA
Ann Rheum Dis; 1996 Jan; 55(1):47-51. PubMed ID: 8572734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
